S1P as regulator of neonatal mucosal immune development and injury

S1P作为新生儿粘膜免疫发育和损伤的调节剂

基本信息

  • 批准号:
    10219246
  • 负责人:
  • 金额:
    $ 13.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-17 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

SUMMARY Dr. Rusconi has a long-standing interest in host microbial interactions. Her work has focused on infants born preterm, who are exceptionally prone to life-threatening gut-associated pathology, most notably necrotizing enterocolitis (NEC). The absence of preventive strategies for NEC and its abysmal outcomes, compelled Dr. Rusconi to perform a broad range metabolomics analysis of pre-event NEC specimens to better understand its pathophysiology. A unique sphingolipid profile emerged, which was confirmed in a larger cohort by targeted mass spectrometry. Sphingolipids perform diverse functions in the human body. Sphingosine-1-phosphate (S1P), a sphingolipid metabolite, is an important signaling molecule that promotes lymphocyte migration. The sensing of S1P by S1P receptor 1 (S1P1) is antagonized in vivo by multiple S1P1 agonists, such as SEW2871, through the internalization and degradation of the receptor. By treating neonatal mice with SEW2871 she observed the predicted systemic lymphopenia and and increase in dendritic and T cells in the small intestine lamina propria. The accumulation of these cells in the lamina propria was not observed in adult mice. Aim 1 will focus on identifying age-specific functional responses of the small intestinal lamina propria upon S1P antagonism. Dr. Rusconi will complement pharmacological data with cell-type specific S1P1 KO mice to address cell-specific requirements. The sphingolipid signature and dysbiosis appear in the same pre-NEC interval. Aim 2 focuses on determining their relationship. Germ-free mice will be colonized with dysbiotic or control preterm microbiota to assess impact on sphingolipids. Fecal content from animals used in Aim 1 will be used to determine the impact of S1P antagonism on the microbiota. Finally, in Aim 3, Dr. Rusconi will combine S1P1 antagonism and dysbiotic preterm microbiota with the NEC-like injury model. She will dissect the role of accumulating lymphocyte populations and altered microbiota on exacerbating NEC-like lesions. Completion of this proposal will provide much needed information on the role of S1P signaling in mucosal immunity establishment and its interplay with the microbiota in the maturing intestine, an interval of life during which NEC occurs. Specifically, this K01 award will allow Dr. Rusconi to improve her ability to plan and conduct animal experiments, refine her immunology skills, and provide her with didactic and practical training in grant writing and manuscript preparation, in a highly mentored environment. Dr. Rusconi’s Institution is supporting her effort with a junior faculty appointment, space, and protected time to perform this work. Her advisory committee consists of her primary mentor Dr. Phillip Tarr, co-mentors Drs. Rodney Newberry and Gautam Dantas, who are investigators with complementary expertise in mucosal immunity, microbe-host interactions, animal models of intestinal disease, and human microbiota modeling. Dr. Rusconi’s Career Development Plan adds to her training in biochemistry, molecular biology, microbiology, and bioinformatics. In summary, this K01 grant will provide Dr. Rusconi the skills to launch an independent research career, amalgamating bioinformatics and experimental biology.
概括 Rusconi博士对宿主微生物相互作用具有长期的兴趣。她的工作专注于出生的婴儿 早产,他们非常容易威胁生命的肠道相关病理,最著名的是坏死 小肠结肠炎(NEC)。缺乏NEC及其糟糕结果的预防策略,迫使博士 Rusconi对事件前NEC标本进行广泛的代谢组学分析,以更好地了解其 病理生理学。出现了一个独特的鞘脂曲线,该轮廓已在较大的队列中被靶向确认 质谱法。鞘脂在人体中发挥了潜水功能。鞘氨醇1-磷酸盐 (S1P)是一种鞘脂代谢物,是促进淋巴细胞迁移的重要信号分子。 通过多个S1P1激动剂(例如SEW2871)在体内拮抗S1P受体1(S1P1)对S1P的传感 通过接收器的内在化和降解。通过用SEW2871治疗新生小鼠 观察到了预测的全身淋巴细胞减少症,并增加了小肠中的树突状和T细胞的增加 薄片propria。这些细胞在成年小鼠中未观察到这些细胞在椎板中的积累。目标1意志 专注于识别小肠道层次的特定年龄特异性功能反应在S1P上 对抗。 Rusconi博士将用细胞类型的特定S1P1 KO小鼠补充药物数据来解决 细胞特异性要求。鞘脂的特征和营养不良以相同的NEC间隔出现。目的 2专注于确定他们的关系。无菌小鼠将用失调或对照早产殖民 微生物群评估对鞘脂的影响。 AIM 1中使用的动物的粪便含量将用于确定 S1P拮抗对微生物群的影响。最后,在AIM 3中,Rusconi博士将结合S1P1拮抗作用 具有NEC样损伤模型的不良生物早产。她将剖析积累的作用 淋巴细胞群体和恶化NEC样病变的微生物群改变。完成此提案 将提供有关S1P信号在粘膜免疫建立及其的作用的急需信息 在成熟的肠道中与微生物群的相互作用,这是NEC发生的生活间隔。具体来说, 这项K01奖将使Rusconi博士能够提高她计划和进行动物实验的能力,改进她 免疫学技能,并在赠款写作和手稿准备方面为她提供教学和实践培训, 在备受推崇的环境中。 Rusconi博士的机构正在支持她与初级教师的努力 约会,空间和保护这项工作的时间。她的咨询委员会由她的主要 导师菲利普·塔尔(Phillip Tarr)博士,联合委托人博士。罗德尼·纽伯里(Rodney Newberry)和高塔·丹塔斯(Gautam Dantas) 粘膜免疫,微生物宿主相互作用,肠道疾病动物模型的互补专业知识, 和人类微生物群建模。 Rusconi博士的职业发展计划增加了她的生物化学培训, 分子生物学,微生物学和生物信息学。总而言之,这项K01赠款将为Rusconi博士提供 启动独立研究职业,合并生物信息学和实验生物学的技能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brigida Agnese Rusconi其他文献

Brigida Agnese Rusconi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brigida Agnese Rusconi', 18)}}的其他基金

S1P as regulator of neonatal mucosal immune development and injury
S1P作为新生儿粘膜免疫发育和损伤的调节剂
  • 批准号:
    10039799
  • 财政年份:
    2020
  • 资助金额:
    $ 13.54万
  • 项目类别:
S1P as regulator of neonatal mucosal immune development and injury
S1P作为新生儿粘膜免疫发育和损伤的调节剂
  • 批准号:
    10614963
  • 财政年份:
    2020
  • 资助金额:
    $ 13.54万
  • 项目类别:
S1P as regulator of neonatal mucosal immune development and injury
S1P作为新生儿粘膜免疫发育和损伤的调节剂
  • 批准号:
    10397640
  • 财政年份:
    2020
  • 资助金额:
    $ 13.54万
  • 项目类别:

相似国自然基金

时空序列驱动的神经形态视觉目标识别算法研究
  • 批准号:
    61906126
  • 批准年份:
    2019
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
  • 批准号:
    41901325
  • 批准年份:
    2019
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
  • 批准号:
    61802133
  • 批准年份:
    2018
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
  • 批准号:
    61872252
  • 批准年份:
    2018
  • 资助金额:
    64.0 万元
  • 项目类别:
    面上项目
针对内存攻击对象的内存安全防御技术研究
  • 批准号:
    61802432
  • 批准年份:
    2018
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Investigating the coordinated endothelial-epithelial interactions in adult hair cycle of mouse skin
研究小鼠皮肤成年毛发周期中协调的内皮-上皮相互作用
  • 批准号:
    10674132
  • 财政年份:
    2023
  • 资助金额:
    $ 13.54万
  • 项目类别:
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma
一种用于治疗 B 系急性淋巴细胞白血病/淋巴瘤的新型 VpreB1 抗体药物偶联物
  • 批准号:
    10651082
  • 财政年份:
    2023
  • 资助金额:
    $ 13.54万
  • 项目类别:
The Role of Bone Sialoprotein in Modulating Periodontal Development and Repair
骨唾液酸蛋白在调节牙周发育和修复中的作用
  • 批准号:
    10752141
  • 财政年份:
    2023
  • 资助金额:
    $ 13.54万
  • 项目类别:
In vivo feasibility of a smart needle ablation treatment for liver cancer
智能针消融治疗肝癌的体内可行性
  • 批准号:
    10699190
  • 财政年份:
    2023
  • 资助金额:
    $ 13.54万
  • 项目类别:
LRP1 as a novel regulator of CXCR4 in adult neural stem cells and post-stroke response
LRP1 作为成体神经干细胞和中风后反应中 CXCR4 的新型调节剂
  • 批准号:
    10701231
  • 财政年份:
    2023
  • 资助金额:
    $ 13.54万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了